Hantech Bio-Technology Co., Ltd. Statistics
Hantech Bio-Technology Co., Ltd. (1294) Stock Statistics & Valuation Metrics
Total Valuation
Hantech Bio-Technology Co., Ltd. has a market cap or net worth of TWD 1.62B. The enterprise value is TWD 2.61B.
- Market Cap
- TWD 1.62B
- Enterprise Value
- TWD 2.61B
Share Statistics
Hantech Bio-Technology Co., Ltd. has 36,625,874 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 36,625,874
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Hantech Bio-Technology Co., Ltd.’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 14.55%.
- Return on Equity (ROE)
- 0.17
- Return on Assets (ROA)
- 0.12
- Return on Invested Capital (ROIC)
- 14.55%
- Return on Capital Employed (ROCE)
- 0.19
- Revenue Per Employee
- 5.06M
- Profits Per Employee
- 903.14K
- Employee Count
- 154
- Asset Turnover
- 0.67
- Inventory Turnover
- 4.41
Valuation Ratios
The current PE Ratio of Hantech Bio-Technology Co., Ltd. is 11.43. Hantech Bio-Technology Co., Ltd.’s PEG ratio is -0.98.
- PE Ratio
- 11.43
- PS Ratio
- 1.88
- PB Ratio
- 1.97
- Price to FCF
- 13.50
- Price to Operating Cash Flow
- 10.60
- PEG Ratio
- -0.98
Income Statement
In the last 12 months, Hantech Bio-Technology Co., Ltd. had revenue of 778.54M and earned 139.08M in profits. Earnings per share was 4.60.
- Revenue
- 778.54M
- Gross Profit
- 283.81M
- Operating Income
- 172.98M
- Pretax Income
- 173.01M
- Net Income
- 139.08M
- EBITDA
- 211.15M
- Earnings Per Share (EPS)
- 4.60
Cash Flow
In the last 12 months, operating cash flow was 152.17M and capital expenditures -31.58M, giving a free cash flow of 120.59M billion.
- Operating Cash Flow
- 152.17M
- Free Cash Flow
- 120.59M
- Free Cash Flow per Share
- 3.35
Dividends & Yields
Hantech Bio-Technology Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 6.73%
- Dividend Per Share
- ―
- Dividend Yield
- 6.73%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 7.41%
- Earnings Yield
- 8.69%
Stock Price Statistics
- Beta
- 0.10
- 52-Week Price Change
- -28.05%
- 50-Day Moving Average
- 50.36
- 200-Day Moving Average
- 59.35
- Relative Strength Index (RSI)
- 18.78
- Average Volume (3m)
- 19.69K
Important Dates
Hantech Bio-Technology Co., Ltd. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Hantech Bio-Technology Co., Ltd. as a current ratio of 2.40, with Debt / Equity ratio of 13.66%
- Current Ratio
- 2.40
- Quick Ratio
- 1.95
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- -0.64
- Interest Coverage Ratio
- 58.11
Taxes
In the past 12 months, Hantech Bio-Technology Co., Ltd. has paid 33.93M in taxes.
- Income Tax
- 33.93M
- Effective Tax Rate
- 0.20
Enterprise Valuation
Hantech Bio-Technology Co., Ltd. EV to EBITDA ratio is 7.63, with an EV/FCF ratio of 12.20.
- EV to Sales
- 1.70
- EV to EBITDA
- 7.63
- EV to Free Cash Flow
- 12.20
- EV to Operating Cash Flow
- 9.67
Balance Sheet
Hantech Bio-Technology Co., Ltd. has TWD 374.05M in cash and marketable securities with TWD 107.40M in debt, giving a net cash position of TWD 266.65M billion.
- Cash & Marketable Securities
- TWD 374.05M
- Total Debt
- TWD 107.40M
- Net Cash
- TWD 266.65M
- Net Cash Per Share
- TWD 7.28
- Tangible Book Value Per Share
- TWD 14.48
Margins
Gross margin is 34.35%, with operating margin of 19.89%, and net profit margin of 16.22%.
- Gross Margin
- 34.35%
- Operating Margin
- 19.89%
- Pretax Margin
- 20.18%
- Net Profit Margin
- 16.22%
- EBITDA Margin
- 22.29%
- EBIT Margin
- 20.03%
Analyst Forecast
The average price target for Hantech Bio-Technology Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 20.43%
- EPS Growth Forecast
- 4.47%
